Literature DB >> 15731223

Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents.

Choong-Tat Keng1, Aihua Zhang, Shuo Shen, Kuo-Ming Lip, Burtram C Fielding, Timothy H P Tan, Chih-Fong Chou, Chay Boon Loh, Sifang Wang, Jianlin Fu, Xiaoming Yang, Seng Gee Lim, Wanjin Hong, Yee-Joo Tan.   

Abstract

The spike (S) protein of the severe acute respiratory syndrome coronavirus (SARS-CoV) interacts with cellular receptors to mediate membrane fusion, allowing viral entry into host cells; hence it is recognized as the primary target of neutralizing antibodies, and therefore knowledge of antigenic determinants that can elicit neutralizing antibodies could be beneficial for the development of a protective vaccine. Here, we expressed five different fragments of S, covering the entire ectodomain (amino acids 48 to 1192), as glutathione S-transferase fusion proteins in Escherichia coli and used the purified proteins to raise antibodies in rabbits. By Western blot analysis and immunoprecipitation experiments, we showed that all the antibodies are specific and highly sensitive to both the native and denatured forms of the full-length S protein expressed in virus-infected cells and transfected cells, respectively. Indirect immunofluorescence performed on fixed but unpermeabilized cells showed that these antibodies can recognize the mature form of S on the cell surface. All the antibodies were also able to detect the maturation of the 200-kDa form of S to the 210-kDa form by pulse-chase experiments. When the antibodies were tested for their ability to inhibit SARS-CoV propagation in Vero E6 culture, it was found that the anti-SDelta10 antibody, which was targeted to amino acid residues 1029 to 1192 of S, which include heptad repeat 2, has strong neutralizing activities, suggesting that this region of S carries neutralizing epitopes and is very important for virus entry into cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15731223      PMCID: PMC1075733          DOI: 10.1128/JVI.79.6.3289-3296.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  35 in total

1.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome.

Authors:  Christian Drosten; Stephan Günther; Wolfgang Preiser; Sylvie van der Werf; Hans-Reinhard Brodt; Stephan Becker; Holger Rabenau; Marcus Panning; Larissa Kolesnikova; Ron A M Fouchier; Annemarie Berger; Ana-Maria Burguière; Jindrich Cinatl; Markus Eickmann; Nicolas Escriou; Klaus Grywna; Stefanie Kramme; Jean-Claude Manuguerra; Stefanie Müller; Volker Rickerts; Martin Stürmer; Simon Vieth; Hans-Dieter Klenk; Albert D M E Osterhaus; Herbert Schmitz; Hans Wilhelm Doerr
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

2.  Interference of coronavirus infection by expression of immunoglobulin G (IgG) or IgA virus-neutralizing antibodies.

Authors:  J Castilla; I Sola; L Enjuanes
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

Review 3.  Coronavirus spike proteins in viral entry and pathogenesis.

Authors:  T M Gallagher; M J Buchmeier
Journal:  Virology       Date:  2001-01-20       Impact factor: 3.616

4.  The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex.

Authors:  Berend Jan Bosch; Ruurd van der Zee; Cornelis A M de Haan; Peter J M Rottier
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

5.  A novel coronavirus associated with severe acute respiratory syndrome.

Authors:  Thomas G Ksiazek; Dean Erdman; Cynthia S Goldsmith; Sherif R Zaki; Teresa Peret; Shannon Emery; Suxiang Tong; Carlo Urbani; James A Comer; Wilina Lim; Pierre E Rollin; Scott F Dowell; Ai-Ee Ling; Charles D Humphrey; Wun-Ju Shieh; Jeannette Guarner; Christopher D Paddock; Paul Rota; Barry Fields; Joseph DeRisi; Jyh-Yuan Yang; Nancy Cox; James M Hughes; James W LeDuc; William J Bellini; Larry J Anderson
Journal:  N Engl J Med       Date:  2003-04-10       Impact factor: 91.245

6.  The SARS-CoV S glycoprotein: expression and functional characterization.

Authors:  Xiaodong Xiao; Samitabh Chakraborti; Anthony S Dimitrov; Kosi Gramatikoff; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2003-12-26       Impact factor: 3.575

7.  Comparative full-length genome sequence analysis of 14 SARS coronavirus isolates and common mutations associated with putative origins of infection.

Authors:  Yi Jun Ruan; Chia Lin Wei; Ai Ling Ee; Vinsensius B Vega; Herve Thoreau; Se Thoe Yun Su; Jer-Ming Chia; Patrick Ng; Kuo Ping Chiu; Landri Lim; Tao Zhang; Chan Kwai Peng; Ean Oon Lynette Lin; Ng Mah Lee; Sin Leo Yee; Lisa F P Ng; Ren Ee Chee; Lawrence W Stanton; Philip M Long; Edison T Liu
Journal:  Lancet       Date:  2003-05-24       Impact factor: 79.321

8.  Effects of a SARS-associated coronavirus vaccine in monkeys.

Authors:  Wentao Gao; Azaibi Tamin; Adam Soloff; Leonardo D'Aiuto; Edward Nwanegbo; Paul D Robbins; William J Bellini; Simon Barratt-Boyes; Andrea Gambotto
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

9.  Aetiology: Koch's postulates fulfilled for SARS virus.

Authors:  Ron A M Fouchier; Thijs Kuiken; Martin Schutten; Geert van Amerongen; Gerard J J van Doornum; Bernadette G van den Hoogen; Malik Peiris; Wilina Lim; Klaus Stöhr; Albert D M E Osterhaus
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

10.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.

Authors:  Wenhui Li; Michael J Moore; Natalya Vasilieva; Jianhua Sui; Swee Kee Wong; Michael A Berne; Mohan Somasundaran; John L Sullivan; Katherine Luzuriaga; Thomas C Greenough; Hyeryun Choe; Michael Farzan
Journal:  Nature       Date:  2003-11-27       Impact factor: 49.962

View more
  58 in total

1.  Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus.

Authors:  Kuo-Ming Lip; Shuo Shen; Xiaoming Yang; Choong-Tat Keng; Aihua Zhang; Hsueh-Ling Janice Oh; Zhi-Hong Li; Le-Ann Hwang; Chih-Fong Chou; Burtram C Fielding; Timothy H P Tan; Josef Mayrhofer; Falko G Falkner; Jianlin Fu; Seng Gee Lim; Wanjin Hong; Yee-Joo Tan
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.

Authors:  Yuxian He; Jingjing Li; Susanne Heck; Sara Lustigman; Shibo Jiang
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain.

Authors:  Christopher E Yi; Lei Ba; Linqi Zhang; David D Ho; Zhiwei Chen
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

4.  A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.

Authors:  Lanying Du; Guangyu Zhao; Chris C S Chan; Lin Li; Yuxian He; Yusen Zhou; Bo-Jian Zheng; Shibo Jiang
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

5.  Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).

Authors:  Mavanur R Suresh; Pravin K Bhatnagar; Dipankar Das
Journal:  J Pharm Pharm Sci       Date:  2008-04-19       Impact factor: 2.327

6.  Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.

Authors:  Jie Li; Laura Ulitzky; Erica Silberstein; Deborah R Taylor; Raphael Viscidi
Journal:  Viral Immunol       Date:  2013-04       Impact factor: 2.257

7.  Synthetic reconstruction of zoonotic and early human severe acute respiratory syndrome coronavirus isolates that produce fatal disease in aged mice.

Authors:  Barry Rockx; Timothy Sheahan; Eric Donaldson; Jack Harkema; Amy Sims; Mark Heise; Raymond Pickles; Mark Cameron; David Kelvin; Ralph Baric
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

Review 8.  Coronaviruses in humans and animals: the role of bats in viral evolution.

Authors:  Amr El-Sayed; Mohamed Kamel
Journal:  Environ Sci Pollut Res Int       Date:  2021-03-02       Impact factor: 5.190

Review 9.  SARS vaccine development.

Authors:  Shibo Jiang; Yuxian He; Shuwen Liu
Journal:  Emerg Infect Dis       Date:  2005-07       Impact factor: 6.883

Review 10.  The spike protein of SARS-CoV--a target for vaccine and therapeutic development.

Authors:  Lanying Du; Yuxian He; Yusen Zhou; Shuwen Liu; Bo-Jian Zheng; Shibo Jiang
Journal:  Nat Rev Microbiol       Date:  2009-02-09       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.